EBITDA: Income before interest, taxes, depreciation and amortization.
Immunome, Inc. (IMNM) had EBITDA of $-224.00M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$6.94M |
|
$-212.39M |
|
-- |
|
$6.94M |
|
$231.05M |
|
$-224.11M |
|
$11.72M |
|
$-212.39M |
|
$-212.39M |
|
$-212.39M |
|
$-212.39M |
|
$-212.39M |
|
$-212.39M |
|
$-224.11M |
|
|
EBITDA |
$-224.00M |
87.35M |
|
87.35M |
|
$-2.43 |
|
$-2.43 |
|
| Balance Sheet Financials | |
$660.78M |
|
$14.64M |
|
$22.41M |
|
$683.19M |
|
$44.99M |
|
-- |
|
$3.85M |
|
$48.84M |
|
$634.34M |
|
$634.34M |
|
$634.34M |
|
113.13M |
|
| Cash Flow Statement Financials | |
$-190.92M |
|
$60.80M |
|
$640.36M |
|
$143.45M |
|
$653.69M |
|
$510.24M |
|
$25.69M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.69 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-3228.83% |
|
-3228.83% |
|
-3227.16% |
|
-3059.99% |
|
-3059.99% |
|
$-200.60M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-33.48% |
|
-33.48% |
|
-31.09% |
|
-33.48% |
|
$5.61 |
|
$-2.30 |
|
$-2.19 |
|